Table 1 Characteristics of the 150 patients at baseline at time of randomisation
Prednisolone group, n = 64No prednisolone group, n = 86p Value
Age, years*53 (14)57 (12)0.027
Female sex64.1%65.1%0.894
Duration of rheumatoid arthritis (months)*6 (4)6 (3)0.633
Rheumatoid factor positivity64.1%63,5%0.947
DAS28*5.4 (1.25)5.5 (0.99)0.629
HAQ score*1.03 (0.56)0.98 (0.61)0.608
Total Sharp score†1.0 (0.0–4.5)1.3 (0.0–5.0)0.795
Erosion score†0.5 (0.0–1.5)0.5 (0.0–1.8)0.858
Joint space narrowing†0.0 (0.0–3.0)1.0 (0.0–3.0)0.541
L2–4, BMD*1.18 (0.15)1.19 (0.21)0.72
L2–4, Z-score*0.33 (1.09)0.85 (1.68)0.023
Femur neck, BMD*0.92 (0.15)0.93 (0.16)0.50
Femur neck, Z-score*0.17 (1.06)0.39 (1.07)0.21
  • BMD, bone mineral density; DAS28, 28-joint count disease activity score; HAQ, Health Assessment Questionnaire.

  • p Values in bold are those that are significant.

  • *Values are mean (SD).

  • †Medians with interquartile ranges.